WEKO3
アイテム
{"_buckets": {"deposit": "ded64c88-f605-4727-bbbc-d51b43b0d208"}, "_deposit": {"created_by": 2, "id": "5814", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "5814"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00005814", "sets": ["9"]}, "author_link": ["24897", "24899", "24912", "24906", "24898", "24908", "24900", "24901", "24910", "24902", "24909", "24911", "24905", "24904", "24907", "24903"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "502", "bibliographicPageStart": "497", "bibliographicVolumeNumber": "74", "bibliographic_titles": [{"bibliographic_title": "Cancer Chemotherapy and Pharmacology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Amrubicin is active in the treatment of extensive-disease small cell lung cancer (ED-SCLC), and carboplatin is an analogue of cisplatin with less non-hematological toxicity. Purpose: The purpose of this study was to determine the efficacy and toxicity of amrubicin and carboplatin combination chemotherapy for previously untreated patients with ED-SCLC. Patients and methods: Eligibility criteria were chemotherapy-naive ED-SCLC patients, performance status 0-1, age ?75, and adequate hematological, hepatic and renal function. Based on the phase I study, the patients received amrubicin 35 mg/m2 i.v. infusion on days 1, 2, and 3, and carboplatin AUC 5 i.v. infusion on day 1. Four cycles of chemotherapy were repeated every 3 weeks. Results: Thirty-five patients were enrolled, and 34 patients were eligible and assessable for response, toxicity, and survival. Patients\u0027 characteristics were as follows: male/female = 26/8; performance status 0/1 = 4/30; median age (range) = 64 (41-75); stage IV = 34. Evaluation of responses was 6 complete response, 21 partial response, and 7 stable disease (response rate 79.4 %, 95 % CI 63.6-88.5 %). Grade 3 and 4 leukopenia, neutropenia, and thrombocytopenia occurred in 59, 82, and 26 %, respectively. There were no treatment-related deaths or pneumonitis. Three patients experienced hypotension as an amrubicin infusion reaction. The median progression-free survival time was 6.5 months. The median overall survival time and 1-, 2-, and 3-year survival rates were 15.6 months, and 63, 28, and 7 %, respectively. Conclusions: Amrubicin and carboplatin were effective and tolerable as chemotherapy for previously untreated patients with ED-SCLC. Further investigation of amrubicin and carboplatin is warranted.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Cancer Chemotherapy and Pharmacology, 74(3), pp.497-502; 2014", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer Verlag"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s00280-014-2527-4", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2014 Springer-Verlag."}, {"subitem_rights": "The final publication is available at link.springer.com"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03445704", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14320843", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ikeda, Takaya"}], "nameIdentifiers": [{"nameIdentifier": "24897", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "24898", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Yoichi"}], "nameIdentifiers": [{"nameIdentifier": "24899", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kinoshita, Akitoshi"}], "nameIdentifiers": [{"nameIdentifier": "24900", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Senju, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "24901", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakano, Hirofumi"}], "nameIdentifiers": [{"nameIdentifier": "24902", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kitazaki, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "24903", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ogawara, Daiki"}], "nameIdentifiers": [{"nameIdentifier": "24904", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Taniguchi, Hirokazu"}], "nameIdentifiers": [{"nameIdentifier": "24905", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Motoshima, Kohei"}], "nameIdentifiers": [{"nameIdentifier": "24906", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "24907", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakatomi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "24908", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimada, Midori"}], "nameIdentifiers": [{"nameIdentifier": "24909", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagashima, Seiji"}], "nameIdentifiers": [{"nameIdentifier": "24910", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsukamoto, Kazuhiro"}], "nameIdentifiers": [{"nameIdentifier": "24911", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "24912", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CCP74_497.pdf", "filesize": [{"value": "161.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 161400.0, "url": {"label": "CCP74_497.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/5814/files/CCP74_497.pdf"}, "version_id": "d43bb49a-a244-4c26-a654-64aa6b1a8e33"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Amrubicin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Carboplatin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Phase II study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Small cell lung cancer", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/34902", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-10-01"}, "publish_date": "2015-10-01", "publish_status": "0", "recid": "5814", "relation": {}, "relation_version_is_last": true, "title": ["A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer"], "weko_shared_id": -1}
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer
http://hdl.handle.net/10069/34902
http://hdl.handle.net/10069/3490296c3b46b-72a8-4ba2-91bc-67c3a7a0c78f
名前 / ファイル | ライセンス | アクション |
---|---|---|
CCP74_497.pdf (161.4 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-10-01 | |||||
タイトル | ||||||
タイトル | A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Amrubicin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Carboplatin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Phase II study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Small cell lung cancer | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ikeda, Takaya
× Ikeda, Takaya× Fukuda, Minoru× Nakamura, Yoichi× Kinoshita, Akitoshi× Senju, Hiroaki× Nakano, Hirofumi× Kitazaki, Takeshi× Ogawara, Daiki× Taniguchi, Hirokazu× Motoshima, Kohei× Yamaguchi, Hiroyuki× Nakatomi, Katsumi× Shimada, Midori× Nagashima, Seiji× Tsukamoto, Kazuhiro× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: Amrubicin is active in the treatment of extensive-disease small cell lung cancer (ED-SCLC), and carboplatin is an analogue of cisplatin with less non-hematological toxicity. Purpose: The purpose of this study was to determine the efficacy and toxicity of amrubicin and carboplatin combination chemotherapy for previously untreated patients with ED-SCLC. Patients and methods: Eligibility criteria were chemotherapy-naive ED-SCLC patients, performance status 0-1, age ?75, and adequate hematological, hepatic and renal function. Based on the phase I study, the patients received amrubicin 35 mg/m2 i.v. infusion on days 1, 2, and 3, and carboplatin AUC 5 i.v. infusion on day 1. Four cycles of chemotherapy were repeated every 3 weeks. Results: Thirty-five patients were enrolled, and 34 patients were eligible and assessable for response, toxicity, and survival. Patients' characteristics were as follows: male/female = 26/8; performance status 0/1 = 4/30; median age (range) = 64 (41-75); stage IV = 34. Evaluation of responses was 6 complete response, 21 partial response, and 7 stable disease (response rate 79.4 %, 95 % CI 63.6-88.5 %). Grade 3 and 4 leukopenia, neutropenia, and thrombocytopenia occurred in 59, 82, and 26 %, respectively. There were no treatment-related deaths or pneumonitis. Three patients experienced hypotension as an amrubicin infusion reaction. The median progression-free survival time was 6.5 months. The median overall survival time and 1-, 2-, and 3-year survival rates were 15.6 months, and 63, 28, and 7 %, respectively. Conclusions: Amrubicin and carboplatin were effective and tolerable as chemotherapy for previously untreated patients with ED-SCLC. Further investigation of amrubicin and carboplatin is warranted. | |||||
書誌情報 |
Cancer Chemotherapy and Pharmacology 巻 74, 号 3, p. 497-502, 発行日 2014-09 |
|||||
出版者 | ||||||
出版者 | Springer Verlag | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 03445704 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14320843 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s00280-014-2527-4 | |||||
権利 | ||||||
権利情報 | c 2014 Springer-Verlag. | |||||
権利 | ||||||
権利情報 | The final publication is available at link.springer.com | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Cancer Chemotherapy and Pharmacology, 74(3), pp.497-502; 2014 |